Anticorps Polyclonal de lapin anti-NFYA

• Phare
• Validé par KD/KO

NFYA Polyclonal Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris et plus (1)

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

Publications(5)

N° de cat : 12981-1-AP

Synonymes

NF-YA, NF YA, HAP2, CBF B, CBF A

---

Galerie de données de validation

• 

  WB analysis of HEK-293 using 12981-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 12981-1-AP (NFYA antibody) at dilution of 1:200 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HT-1080 using 12981-1-AP

  HT-1080 cells were subjected to SDS PAGE followed by western blot with 12981-1-AP (NFYA antibody) at dilution of 1:100 incubated at room temperature for 1.5 hours.

• 

  WB analysis of K-562 using 12981-1-AP

  K-562 cells were subjected to SDS PAGE followed by western blot with 12981-1-AP (NFYA antibody) at dilution of 1:100 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 12981-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 12981-1-AP (NFYA antibody) at dilution of 1:200 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 12981-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 12981-1-AP (NFYA antibody) at dilution of 1:200 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human colon cancer using 12981-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 12981-1-AP (NFYA antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 12981-1-AP

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 12981-1-AP (NFYA antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 12981-1-AP

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 12981-1-AP (NFYA antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 12981-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 12981-1-AP (NFYA antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of HepG2 using 12981-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HepG2 cells using NFYA antibody (12981-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2), CL594-Phalloidin (red).

---

Applications testées

• Résultats positifs en WB: cellules HEK-293, cellules HeLa, cellules HT-1080, cellules Jurkat, cellules K-562
• Résultats positifs en IHC: tissu de cancer du côlon humain, tissu de cancer de la prostate humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules HepG2,

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:1000
• Immunohistochimie (IHC): IHC : 1:250-1:1000
• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 2 publications below
• WB: See 4 publications below
• IHC: See 1 publications below

Informations sur le produit

12981-1-AP cible NFYA dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: NFYA Protéine recombinante Ag3604
• Nom complet: nuclear transcription factor Y, alpha
• Masse moléculaire calculée: 318aa,34 kDa; 347aa,39 kDa
• Poids moléculaire observé: 40 kDa, 46 kDa
• Numéro d’acquisition GenBank: BC039244
• Symbole du gène: NFYA
• Identification du gène (NCBI): 4800
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

NFYA, also named as Nuclear transcription factor Y subunit alpha, is a 347 amino acid protein, which contains 1 NFYA/HAP2-type DNA-binding domain and belongs to the NFYA/HAP2 subunit family. NFYA exists the two 41- to 45-kDa isoforms of NF-YA ( 11287613 ). NFYA is a component of the sequence-specific heterotrimeric transcription factor (NF-Y) which specifically recognizes a 5'-CCAAT-3' box motif found in the promoters of its target genes. NF-Y can function as both an activator and a repressor, depending on its interacting cofactors. NF-YA positively regulates the transcription of the core clock component ARNTL/BMAL1

Publications

Species	Application	Title
mouse	IHC	Nature; Divergent transcriptional regulation of astrocyte reactivity across disorders.; Authors - Joshua E Burda
human,mouse	WB	J Virol; Minute Virus of Mice (MVM) inhibits transcription of the cyclin B1 gene during infection.; Authors - Matthew S Fuller
human	WB	Int J Oncol; Gene regulatory network construction identified NFYA as a diffuse subtype-specific prognostic factor in gastric cancer.; Authors - Bin Cao ; KD Validated
rat	WB	Cell Death Dis; PRMT5 critically mediates TMAO-induced inflammatory response in vascular smooth muscle cells.; Authors - He Liu ; KD Validated
human	WB	Life Sci; SNORD9 promotes ovarian cancer tumorigenesis via METTL3/IGF2BP2-mediated NFYA m6A modification and is a potential target for antisense oligonucleotide therapy; Authors - Shuo Chen

{{ptg:RelatedPrimaryAntibodies}}